Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma

Acta Neuropathologica

Volumn 125, Issue 3, 2013, Pages 373-384

  Dubuc, Adrian M ^a,b   Remke, Marc ^a,b   Korshunov, Andrey ^c,d   Northcott, Paul A ^c   Zhan, Shing H ^e   Mendez Lago, Maria ^e   Kool, Marcel ^c   Jones, David T W ^c   Unterberger, Alexander ^a   Morrissy, A Sorana ^a   Shih, David ^a,b   Peacock, John ^a,b   Ramaswamy, Vijay ^a,b   Rolider, Adi ^a   Wang, Xin ^a,b   Witt, Hendrik ^c   Hielscher, Thomas ^c   Hawkins, Cynthia ^a,b   Vibhakar, Rajeev ^f   Croul, Sidney ^g   Rutka, James T ^a,b   Weiss, William A ^h   Jones, Steven J M ^e   Eberhart, Charles G ⁱ   Marra, Marco A ^e   Pfister, Stefan M ^c   Taylor, Michael D ^a,b   more..

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

^f UNIVERSITY OF COLORADO   (United States)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Histone lysine methylation; KDM6A; Medulloblastoma; MLL2; PRC2

Indexed keywords

HISTONE H3; LYSINE; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTOR EZH2;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; EZH2 GENE; GENE DOSAGE; GENE INACTIVATION; GENE SILENCING; HISTONE CODE; HISTONE METHYLATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KDM6A GENE; KDM6B GENE; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MEDULLOBLASTOMA; MLL GENE; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PHENOTYPIC VARIATION; PRC2 GENE; PRIORITY JOURNAL; SOMATIC MUTATION; TUMOR GENE; VALIDATION PROCESS;

BASE SEQUENCE; CEREBELLAR NEOPLASMS; COHORT STUDIES; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME; HISTONE DEMETHYLASES; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LYSINE; MALE; MEDULLOBLASTOMA; METHYLATION; MUTATION; NEOPLASM PROTEINS; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84878857067     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-012-1070-9     Document Type: Article

References (25)

1. Alimova I, Venkataraman S, Harris P, Marquez VE, Northcott PA (2012) Targeting the enhancer of zeste homologue 2 in medulloblastoma. Int J Cancer doi: 10.1002/ijc.27455
2. Andreu-Vieyra CV, Chen R, Agno JE, Glaser S, Anastassiadis K, et al. (2010) MLL2 is required in oocytes for bulk histone 3 lysine 4 trimethylation and transcriptional silencing. PLoS Biol 8(8):e1000453
3. Bots M, Johnstone RW (2009) Rational combinations using HDAC inhibitors. Clin Cancer Res 15(12):3970-3977
4. Ecke I, Petry F, Rosenberger A, Tauber S, Monkemeyer S, et al. (2009) Antitumor effects of a combined 5-aza-2′deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. Cancer Res 69(3):887-895
5. Ellison DW, Onilude OE, Lindsey JC, Lusher ME, Weston CL, et al. (2005) beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 23(31):7951-7957
6. Fejes AP, Khodabakhshi AH, Birol I, Jones SJ (2011) Human variation database: an open-source database template for genomic discovery. Bioinformatics 27(8):1155-1156
7. Glaser S, Schaft J, Lubitz S, Vintersten K, van der Hoeven F, et al. (2006) Multiple epigenetic maintenance factors implicated by the loss of Mll2 in mouse development. Development 133(8):1423-1432
8. van Haaften G, Dalgliesh GH, Davies H, Chen L, Bignell G, et al. (2009) Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 41(5):521-523
9. Jones DT, Jager N, Kool M, Zichner T, Hutter B, et al. (2012) Dissecting the genomic complexity underlying medulloblastoma. Nature 488(7409):100-105
10. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, et al. (2008) Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PloS One 3(8):e3088
11. Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, et al. (2012) Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 123(4):473-484
12. Lafay-Cousin L, Bouffet E, Hawkins C, Amid A, Huang A, et al. (2009) Impact of radiation avoidance on survival and neurocognitive outcome in infant medulloblastoma. Curr Oncol 16(6):21-28
13. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, et al. (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. doi: 10.1038/nature11606
14. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, et al. (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476(7360):298-303
15. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, et al. (2011) Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29(11):1408-1414
16. Northcott PA, Nakahara Y, Wu X, Feuk L, Ellison DW, et al. (2009) Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 41(4):465-472
17. Parsons DW, Li M, Zhang X, Jones S, Leary RJ, et al. (2011) The genetic landscape of the childhood cancer medulloblastoma. Science 331(6016):435-439
18. Pfaff E, Remke M, Sturm D, Benner A, Witt H, et al. (2010) TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol 28(35):5188-5196
19. Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, et al. (2012) Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488(7409):106-110
20. Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, et al. (2012) Novel mutations target distinct subgroups of medulloblastoma. Nature 488(7409):43-48
21. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, et al. (2009) Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 361(12):1173-1178
22. Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G (2007) Genome regulation by polycomb and trithorax proteins. Cell 128(4):735-745
23. Schuettengruber B, Martinez AM, Iovino N, Cavalli G (2011) Trithorax group proteins: switching genes on and keeping them active. Nat Rev Mol Cell Biol 12(12):799-814
24. Tamayo P, Cho YJ, Tsherniak A, Greulich H, Ambrogio L, et al. (2011) Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. J Clin Oncol 29(11):1415-1423
25. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, et al. (2012) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123(4):465-472